3 documents found, page 1 of 1
A genome-informed higher rank classification of the biotechnologically importan...
Groenewald, M.; Hittinger, C. T.; Bensch, K.; Opulente, D. A.; Shen, X. X.; Li, Y.; Liu, C.; LaBella, A. L.; Zhou, X.; Limtong, S.; Jindamorakot, S.Funding Information: We want to thank Barbara Roberts from the NCBI Taxonomy Team for providing the update of the current fungal names in NCBI Taxonomic database. Masako Takashima is supported by the Institution for Fermentation, Osaka (IFO). Heide-Marie Daniel is supported by the Belgian Science Policy Office grant C5/00/BCCM. Chris Todd Hittinger is supported by the National Science Foundation under Grant Nos...
The Portuguese Society of Rheumatology position paper on the use of biosimilars...
Araújo, Filipe C.; Sepriano, Alexandre; Teixeira, F.; Jesus, D.; Rocha, T. M.; Martins, Paula Andreia; Tenazinha, C.; Cordeiro, A.; Mourão, A. F.Biosimilars are new and more affordable similar versions of previously approved reference biological drugs. Following the approval of the first monoclonal antibody biosimilar in 2013, the Portuguese Society of Rheumatology issued a position paper on the use of biosimilars in rheumatic conditions covering efficacy, safety, extrapolation, interchangeability, substitution and pharmacovigilance. However, as this is...
The Portuguese Society of Rheumatology position paper on the use of biosimilars...
Araújo, F.C.; Sepriano, Alexandre; Teixeira, F.; Jesus, D.; Rocha, T.M.; Martins, P.; Tenazinha, C.; Cordeiro, A.; Mourão, A.F.; Silva, C.; Vaz, C.Biosimilars are new and more affordable similar versions of previously approved reference biological drugs. Following the approval of the first monoclonal antibody biosimilar in 2013, the Portuguese Society of Rheumatology issued a position paper on the use of biosimilars in rheumatic conditions covering efficacy, safety, extrapolation, interchangeability, substitution and pharmacovigilance. However, as this is...